ACADIA Pharmaceuticals (ACAD) Stock: Here’s Why It’s Up!

0

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)

ACADIA Pharmaceuticals is having an incredible day in the market today, and for good reason. Late Friday, the company announced positive news it had received from the FDA. One of the treatments the company has been working on has been approved. Today, we’ll talk about that treatment, how the market reacted to the news, and what we can expect to see from ACAD moving forward. So, let’s get right to it!

Trade smarter and make more money with Tradespoon!

ACAD Announces The Approval Of NUPLAZID

For some time now, ACADIA Pharmaceuticals has been working on a treatment for hallucinations and delusions that are associated with Parkinson’s disease psychosis. That treatment is known as NUPLAZID or pimavanserin. On Friday, the company announced that the FDA has approved NUPLAZID as a breakthrough therapy to treat hallucinations and delusions associated with Parkinson’s disease psychosis. NUPLAZID is the first treatment of its kind, and the only FDA approved treatment designed for this indication. In a statement, Steve Davis, President and CEO at ACAD, had the following to say with regard to the approval:

NUPLAZID represents a major medical advancement for patients with Parkinson’s disease psychosis who suffer from hallucinations and delusions… We are grateful to the many patients and investigators who participated in NUPLAZID’s clinical studies. NUPLAZID represents the culmination of many years of work across our entire organization to bring this novel medicine, discovered by our scientists to patients in need.”

How The Market Reacted To The News

As investors, we know that the news moves the market. Any time positive news is released with regard to a publicly-traded company, we can expect to see gains in the value of the company as a result. Adversely, when negative news is released, we can expect to see declines. Considering the fact that NUPLAZID has been approved, the news surrounding ACAD is overwhelmingly positive. As a result, we’re seeing strong positive movement in the market surrounding the news. Currently (9:27), the stock is trading at $33.96 per share after a gain of $1.66 per share or 5.14% thus far today.

What We Can Expect To See Moving Forward

Moving forward, I have an overwhelmingly bullish opinion with regard to what we can expect to see from ACAD. The reality is that the FDA’s decision to approve NUPLAZID is an overwhelmingly positive decision for ACADIA. Currently, there is a major medical need for the treatment the company is now approved to offer. According to the National Parkinson’s Foundation, in the United States, there are about one million people that suffer from this condition and between four and six million around the world. It is estimated that about 40% of the patients that are dealing with Parkinson’s disease also are forced to deal with Parkinson’s disease psychosis. This means that ACAD has a relatively large audience for the treatment that it has created. Additionally, beyond NUPLAZID, ACAD has an incredibly strong company. They have a wide range of both approved treatments, and treatments that they are working on. With strong management, an incredible team, and great products, it only makes sense that this stock will soar from here.

Don’t waste your time! Click here to find winning trades in minutes!

What Do You Think?

Where do you think ACAD is headed and why? Let us know your opinion in the comments below!

[Image Courtesy of Wikipedia]

Previous articleBlackBerry (BBRY) Stock: Here’s Why It’s A Buy
Next articleExporting Quantitative Easing by The FED!
Hey, Im Joshua, the founder of CNA Finance. I enjoy following the trends in the market and finding the catalysts that are making the moves. If you want to get in contact with me, leave a comment below or email me at CNAFinanceHelp@gmail.com Please keep in mind that I am not an investment advisor and nor is CNA Finance. This is a news and information gathering outlet. We may work directly with some of the companies that we write about. If we have a business relationship with an issuer, we will mention that in the articles. We also have various affiliate relationships with advertisers and may be paid if you sign up for a service that you were referred to through our website.

LEAVE A REPLY

Please enter your comment!
Please enter your name here